Booming Omics in Schistosoma

Yohann Le Govic; Benjamin Gourbal; Jérôme Boissier

doi:10.1016/j.pt.2020.10.010

Booming Omics in Schistosoma

Trends Parasitol. 2021 Jan;37(1):6-8. doi: 10.1016/j.pt.2020.10.010. Epub 2020 Nov 6.

Authors

Yohann Le Govic¹, Benjamin Gourbal², Jérôme Boissier³

Affiliations

¹ Department of Medical Parasitology and Mycology, Amiens University Hospital, Amiens, France; Host-Pathogen Interaction Study Group (GEIHP, EA 3142), UNIV Angers, UNIV Brest, Federative Structure of Research 'Cellular Interactions and Therapeutic Applications', SFR 4208 ICAT, Angers, France.
² IHPE, University of Montpellier, CNRS, Ifremer, University of Perpignan Via Domitia, Perpignan, France.
³ IHPE, University of Montpellier, CNRS, Ifremer, University of Perpignan Via Domitia, Perpignan, France. Electronic address: boissier@univ-perp.fr.

PMID: 33168425
DOI: 10.1016/j.pt.2020.10.010

Abstract

Efforts to eliminate schistosomiasis are hindered by incomplete efficacy of the only FDA-approved antischistosomal drug, praziquantel. By using postgenomic technologies, Wendt et al. and Wang et al. deciphered the function of several genes required for worm survival and pathogenesis, which opens the way for the development of innovative parasite-targeted therapies.

Keywords: RNA interference; blood feeding; praziquantel; proteasome; scRNA-seq; schistosomiasis.

Publication types

Comment

MeSH terms

Animals
Praziquantel / therapeutic use
RNA-Seq
Schistosoma mansoni
Schistosomiasis* / drug therapy
Schistosomicides*

Substances

Schistosomicides
Praziquantel